Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Rheumatic Diseases|July 22, 2017
Tuberculosis and biologics in rheumatology: A special situationRohini Handa, Sundeep Upadhyaya, Sanjiv Kapoor, et al.
Therapeutic Drug Monitoring|June 9, 2023
Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary TuberculosisShanmugam Murugaiha Jeyakumar, Namrata K Bhui, Neeta Singla, et al.
Plos One|February 8, 2013
Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi regionChhavi Porwal, Amit Kaushik, Nayani Makkar, et al.
Plos One|February 20, 2016
Genotypic, Phenotypic and Clinical Validation of GeneXpert in Extra-Pulmonary and Pulmonary Tuberculosis in IndiaUrvashi B Singh, Pooja Pandey, Girija Mehta, et al.
Therapeutic Drug Monitoring|January 1, 2024
Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant TuberculosisAnuj K Bhatnagar, Agibothu Kupparam Hemanthkumar, Mariappan Muthu Vijayalakshmi, et al.
Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine|January 21, 2026
First-ever Experience of Implementing Therapeutic Nutrition for Very Severely Undernourished Adults with TB in Routine Program Settings: A Longitudinal Descriptive StudyHemant Deepak Shewade, Anuj K Bhatnagar, Sanjay Gupta, et al.
The Lancet. Global Health|December 24, 2022
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialLaura Rosu, Jason J Madan, Ewan M Tomeny, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2024
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialChandrasekaran Padmapriyadarsini, Vikas S Oswal, Chetankumar D Jain, et al.
Pageof 3